FDA
-
-
-
-
-
-
-
CytomX Therapeutics (CTMX) Announces FDA Clearance of IND Applications for CX-2051
-
-
-
-
-
-
-
CytomX Therapeutics (CTMX) Announces Phase 2 Study of Praluzatamab Ravtansine Met Primary Endpoint
-
-
-
-
-
-
-
CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
-
-
-
-
-
-
-
CytomX Therapeutics Announces Full-Year 2018 Financial Results
-
-
-
-
-
-
-
Pre-Open Stock Movers 10/04: (CTMX) (CATB) (MYL) Higher; (CLSN) (MNTA) (TEVA) (ODP) Lower (more...)
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

